Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.
Masanori AtsukawaHaruki UojimaAtsushi HiraokaSatoshi KobayashiHidenori ToyodaToshifumi TadaHisashi HidakaShogo IwabuchiKazushi NumataEi ItobayashiNorio ItokawaKazuya KariyamaHideko OhamaNobuhiro HattoriShunji HiroseHiroshi ShibataJoji TaniMichitaka ImaiKazuto TajiriSatoshi MoriyaNaohisa WadaShuitirou IwasakiTaito FukushimaMakoto UenoSatoshi YasudaMasanori AtsukawaKazuhiro NousoShinya FukunishiTsunamasa WatanabeToru IshikawaShinichiro NakamuraManabu MorimotoTatehiro KagawaMichiie SakamotoTakashi KumadaShin MaedaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)
Lenvatinib treatment offers a benefit in highly advanced HCC (tm50%LO or VP4) patients with good liver function or nodular-type tumor. The various characteristics identified in this study might be useful as indicators of lenvatinib treatment in highly advanced HCC with tm50%LO or VP4, which are considered very refractory cancers.
Keyphrases